Reuters logo
4 个月内
BRIEF-Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272
2017年4月4日 / 晚上6点43分 / 4 个月内

BRIEF-Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272

1 分钟阅读

April 4 (Reuters) - Puma Biotechnology Inc:

* Puma Biotechnology presents interim results of Phase II CONTROL trial of PB272 in extended adjuvant treatment of HER2-positive early stage breast cancer at the 2017 AACR annual meeting

* Results of Phase II CONTROL trial showed incidence of grade 3 diarrhea for 137 patients who received loperamide prophylaxis was 30.7%

* For 137 patients who received loperamide prophylaxis in Phase II CONTROL trial, 20.4% discontinued neratinib due to diarrhea

* Reductions seen in incidence of severe neratinib-related diarrhea in CONTROL trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below